+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of NNZ-2591 compared to a placebo in children aged 3 to 12 years with Phelan-McDermid Syndrome. This Phase 3, randomized, double-blind, placebo-controlled study aims to understand how NNZ-2591 may impact symptoms related to this genetic condition. After consent, participants enter a 4-week screening period to determine eligibility and baseline symptom levels. Eligible children are then randomly assigned to receive either NNZ-2591 or a matching placebo, both taken orally twice daily, for 13 weeks. Following treatment, there is a 2-week safety follow-up to monitor any side effects. Throughout the study, participants undergo various assessments including symptom severity scales and caregiver impressions to measure changes. Researchers evaluate the primary outcomes at week 13 using specific tools for symptom change and communication abilities. The total duration of participation is approximately 17 to 19 weeks, including screening, treatment, and follow-up.

Age: 3Years - 12YearsAll GendersPhase 3
18 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating an investigational mRNA seasonal flu vaccine compared to a licensed flu vaccine in adults aged 65 years and older. The study aims to assess the ability of the vaccines to prevent laboratory-confirmed influenza illness, monitor side effects, and measure immune responses during the flu season. This Phase 3 randomized, observer-blind trial is sponsored by GlaxoSmithKline and focuses on flu prevention in older adults. Participants will receive a single injection on Day 1 of either the investigational mRNA seasonal flu vaccine or a licensed, age-appropriate, season-adapted influenza vaccine. The study follows a parallel group design where participants are randomly assigned to one of these two vaccine groups. The follow-up period covers the entire influenza season to assess vaccine efficacy and safety. During the study, participants will be monitored for influenza-like illness confirmed by laboratory tests from Day 15 through the end of the influenza season. Safety assessments include tracking solicited local and systemic side effects from Day 1 to Day 7, unsolicited adverse events up to Day 28, and serious adverse events or special interest adverse events through at least 180 days of follow-up. Blood samples will be collected before dosing and on Day 29 to evaluate immune responses. Participants are followed for safety and efficacy throughout the flu season, with total involvement spanning several months.

Age: 65Years +All GendersPhase 3
163 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety, tolerability, and effectiveness of NNZ-2591 in children with Phelan-McDermid Syndrome in this Phase 3 open-label extension study. The trial focuses on pediatric participants who have previously taken part in related studies and aims to better understand the impact of this treatment over an extended period. Participants who qualify will take NNZ-2591 orally twice daily for a year during the Treatment Period. After completing this 52-week phase, there is a 2-week safety follow-up period to monitor any lasting effects or side effects. The study is designed to assess how well participants tolerate the treatment and to observe any changes in their symptoms. During the study, participants will undergo assessments to confirm eligibility, establish baseline health and symptom severity, and monitor safety through adverse event tracking, ECG, vital signs, and laboratory tests. Researchers will also evaluate treatment effects using specific behavioral and severity scales at 3 and 12 months. The total time commitment for each participant is up to 56 weeks, including treatment and follow-up.

Age: 3Years - 12YearsAll GendersPhase 3
11 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are investigating whether advanced MRI techniques can help predict neurological outcomes in patients who remain comatose after cardiac arrest. This observational study focuses on three main questions whether brain activations measured by stimulus-based functional MRI fMRI, resting state network connectivity measured by resting state fMRI rs-fMRI, and white matter integrity measured by diffusion tensor imaging DTI are associated with favorable neurological recovery. These advanced imaging measures are studied alongside standard clinical MRI and neurological assessments. Participants will undergo specialized MRI scans using stimulus-based fMRI, resting state fMRI, and DTI sequences during their clinical MRI session. These scans provide detailed information about brain function and structure that researchers will analyze to determine their relationships with patient outcomes. The study does not involve experimental treatments but collects imaging data at a single time point during routine MRI. During the study, participants are monitored and followed for six months after their cardiac arrest event. The main outcome measured is the Cerebral Performance Category Score at six months, which reflects neurological function. Secondary outcomes include similar neurological assessments at two weeks. Researchers will use statistical methods to relate MRI findings to these outcomes. Participant care continues as usual, and the study observes how MRI results may inform prognosis over time.

Age: 18Years +All Genders
2 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are investigating potential neurophysiologic biomarkers in females with Rett Syndrome RTT to better understand abnormal brain activity and disease progression. This observational study compares electrophysiological measures from females with RTT to those from typically developing females to identify markers that may help in future intervention studies. The study aims to see how these biomarkers change during clinical changes, remain stable over time in stable individuals, and correlate with RTT severity. Participants will undergo up to eight standardized sessions involving electroencephalogram EEG recordings with auditory and visual evoked potentials AEP and VEP and resting state EEG. Clinical assessments using established measures for RTT will also be collected in affected participants. The study evaluates different electrode types, placement methods, and techniques to reduce movement artifacts to establish best practices for recording. Throughout the study, participants will have repeated neurophysiological assessments correlated with clinical severity and disease staging. Researchers will analyze AEP and VEP latency and amplitude, EEG patterns, and spectral analyses over a 5-year period. These measures aim to provide objective data linked to RTT features. The total involvement includes multiple visits for EEG and clinical assessments, with long-term follow-up to observe biomarker stability and changes.

Age: 1Year - 18YearsFEMALE
6 locations
P

Actively Recruiting

Researchers are evaluating MRTX1719 in patients with advanced, unresectable, or metastatic solid tumors that have a homozygous deletion of the MTAP gene. This Phase 1, open-label, multicenter study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of MRTX1719. The study explores dose and regimen aspects to identify potentially viable treatment approaches. Participants receive MRTX1719, a potent PRMT5-MTA inhibitor, with specified doses administered on certain days. The study begins with dose exploration and may include Phase 1b expansion cohorts to gather additional safety data, pharmacokinetic information, compare effects of food intake, and evaluate bioavailability between capsules and tablets. Early signs of clinical activity are also monitored during these expansions. During the trial, participants undergo mandatory tumor biopsies at baseline and on-study to assess pharmacodynamics unless medically unsafe. Researchers monitor dose-limiting toxicities within 21 days and track treatment-related adverse events for up to 2 years. They also measure objective response rate, duration of response, progression-free survival, and overall survival over 2 years. Laboratory assessments continue for up to 4 years to evaluate long-term effects. This study is sponsored by Bristol-Myers Squibb.

Age: 18Years +All GendersPhase 1
25 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a bivalent vaccine candidate designed to protect adults aged 60 years and older against Respiratory Syncytial Virus RSV and Human Metapneumovirus HMPV. This Phase 12, randomized, observer-blind, placebo-controlled study involves about 2400 participants and aims to assess the vaccines ability to trigger immune responses and monitor its safety. While several RSV vaccines are approved, there is currently no vaccine for preventing HMPV in older adults. Participants will be assigned to one of 11 groups, receiving different doses of the RSVHMPV vaccine, placebo, or one of four control vaccines. The study includes six dose levels of the RSVHMPV vaccine with predefined antigen ratios. Each participant will be followed for approximately 12 months to allow comprehensive evaluation. The study is conducted across multiple centers and uses a parallel group design. During the study, participants will have blood samples taken at baseline, Day 29, and at 3, 6, 9, and 12 months to measure neutralizing antibodies and immunoglobulin G concentrations against RSV and HMPV. Safety will be monitored through reporting of adverse events shortly after vaccination, for several days post-vaccination, and up to six months or throughout the 12-month study period. Biological tests and medical assessments will also be performed to ensure participant safety and collect detailed data on immune response.

Age: 60Years +All GendersPhase 1Phase 2
50 locations
P

Actively Recruiting

Researchers are evaluating the CRUSH curriculum, a behavioral program combined with one-on-one coaching, designed to provide sexual education and improve intimate relationship skills specifically for autistic adults. This pilot clinical trial aims to determine if the curriculum is feasible to deliver, acceptable to participants, and shows early signs of being helpful. The study also seeks to explore how the curriculum works and test the assessment tools for future trials. Participants will engage in 20 sessions of the CRUSH curriculum plus individual coaching. The trial includes a waitlist control group, where some participants receive the intervention immediately and others are invited to participate after the study period. Assessments occur before starting, halfway through, and after completing the curriculum to measure knowledge and behaviors related to dating and sexual health. During the study, participants complete a screening call and confirm their autism diagnosis and abilities. They attend three visits for evaluations and provide feedback after each session. Researchers monitor acceptability and feasibility using rating scales and tests at multiple points throughout the 20-week program. The total participation lasts through these assessments and intervention sessions, helping to gather initial data on this programs impact.

Age: 18Years - 30YearsAll GendersPhase Not Applicable
1 location
G

Actively Recruiting

This research aims to gather real-world data on the outcomes of Boston Scientific neurostimulation systems used for pain management in everyday clinical practice. It focuses on evaluating the long-term effectiveness, economic value, and technical performance of these commercially approved neurostimulation devices when used according to their instructions. Participants will undergo a trial period with a Boston Scientific neurostimulation system for pain. Those who experience positive results from the trial may then receive a permanent implant of the neurostimulation system. The therapy will be personalized based on the investigators judgment and routine site care, following the studys inclusion and exclusion criteria. During the study, participants will be monitored as they receive neurostimulation therapy in real-world settings. Researchers will collect information on treatment outcomes and device performance over time. The study spans from 2012 to 2035, allowing for long-term observation of participants using these neurostimulation systems for pain relief.

Age: 18Years +All Genders
118 locations